Thymosin Alpha-1
1.5 mg · 2×/week
Evidence
- Human Studies
- 25
- Animal Studies
- 30
- Clinical Status
- Off-label
- Confidence
- Moderate
- Long-Term Safety
- Established in the countries where it is an approved drug; not FDA approved in the US
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A naturally occurring thymic peptide that modulates T-cell function and immune response. Marketed outside the US as Zadaxin for chronic hepatitis B/C and as a cancer/immune adjuvant, and studied in various infectious-disease and immune-modulation trials — not FDA approved in the US.
Common Protocols
- 1.5 mg twice weekly, subcutaneous, per typical immune-support protocols
Side Effects
- Injection site reaction
- Generally well-tolerated in trials for its approved (non-US) indications
Interactions
- Immunomodulatory — caution combining with other immune-affecting drugs, or in autoimmune conditions
Practical Details
- Cost
- $$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Research Links
Immune modulation